These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6119205)

  • 21. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.
    Shaffer JL; Houston JB
    Br J Clin Pharmacol; 1985 Apr; 19(4):526-8. PubMed ID: 2859874
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pulmonary diffusing capacity disorder in nonspecific intestinal inflammations unexplainable by acetylation phenotype or treatment with sulfasalazine].
    Bures J; Horácek J; Tilser P; Fixa B; Komárková O; Tichý M; Zaydlar K; Král B
    Cas Lek Cesk; 1986 Jul; 125(29):905-9. PubMed ID: 2873894
    [No Abstract]   [Full Text] [Related]  

  • 24. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
    Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R
    Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemolysis during salicylazosulfapyridine therapy.
    van Hees PA; van Elferen LW; van Rossum JM; van Tongeren JH
    Am J Gastroenterol; 1978 Nov; 70(5):501-5. PubMed ID: 33552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W
    Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desensitization for sulfasalazine skin rash.
    Purdy BH; Philips DM; Summers RW
    Ann Intern Med; 1984 Apr; 100(4):512-4. PubMed ID: 6142671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-performance liquid chromatographic assay of sulfapyridine and acetylsulfapyridine in biological fluids.
    Owerbach J; Johnson NF; Bates TR; Pieniaszek HJ; Jusko WJ
    J Pharm Sci; 1978 Sep; 67(9):1250-3. PubMed ID: 690830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of sulfasalazine in the treatment of inflammatory bowel disease.
    Spector R
    J Iowa Med Soc; 1983 Jun; 73(6):230-4. PubMed ID: 6135735
    [No Abstract]   [Full Text] [Related]  

  • 33. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
    Azad Khan AK; Truelove SC
    Gut; 1980 Aug; 21(8):706-10. PubMed ID: 6107264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulfasalazine therapy in inflammatory bowel disease.
    Das KM
    Gastroenterol Clin North Am; 1989 Mar; 18(1):1-20. PubMed ID: 2563989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary function in patients with inflammatory bowel disease.
    Eade OE; Smith CL; Alexander JR; Whorwell PJ
    Am J Gastroenterol; 1980 Feb; 73(2):154-6. PubMed ID: 6104919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ; McDermott BJ; Roberts SD
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemolytic anemia in patients receiving sulfasalazine.
    Goodacre RL; Ali MA; Vanderlinden B; Hamilton JD; Castelli M; Seaton T
    Digestion; 1978; 17(6):503-8. PubMed ID: 30666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?
    Fischer C; Klotz U
    Ther Drug Monit; 1980; 2(2):153-8. PubMed ID: 6132473
    [No Abstract]   [Full Text] [Related]  

  • 39. [Long-term therapy in ulcerative colitis and Crohn's disease].
    Malchow H
    Fortschr Med; 1979 Aug; 97(29):1253-60. PubMed ID: 457018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotics and inflammatory bowel diseases.
    Gitnick G
    Gastroenterol Clin North Am; 1989 Mar; 18(1):51-6. PubMed ID: 2563991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.